Status:
COMPLETED
The Effect of High Dose N-acetylcysteine on Airtrapping and Airway Resistance in Chronic Obstructive Pulmonary Disease (COPD) Patients
Lead Sponsor:
Kwong Wah Hospital
Conditions:
COPD
Eligibility:
All Genders
40-85 years
Phase:
PHASE4
Brief Summary
This study is to investigate the add-on effect of high dose NAC (600mg tablet twice daily) on reduction of airtrapping and airway resistance in stable COPD patients as well as to study it's effect in ...
Detailed Description
Background: The mucolytic and antioxidant effects of N-acetylcysteine (NAC) may be of great value in treatment of COPD patients. However, previous studies fail to demonstrate the beneficial effect of ...
Eligibility Criteria
Inclusion
- Spirometry diagnosed COPD with FEV1/FVC ratio less than 70% and FEV1 less than 80% predicted
- clinically stable and exacerbation free in the past 4 weeks
- history of at least one COPD exacerbation in the past one year
Exclusion
- patients allergic or intolerant to NAC
- Recent use of NAC in the past one month
- history of asthma, non COPD respiratory disorders like bronchiectasis, pneumoconiosis or any active pulmonary infection
- patients on long term steroid
- patients on long term oxygen therapy or non invasive ventilation
Key Trial Info
Start Date :
February 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2012
Estimated Enrollment :
133 Patients enrolled
Trial Details
Trial ID
NCT01136239
Start Date
February 1 2010
End Date
February 1 2012
Last Update
April 9 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Department
Hong Kong, China